Form 4: Pfizer Executive Douglas M. Lankler Acquires Stock Appreciation Rights
SEC Form 4 Filing
Executive Vice President Douglas M. Lankler acquired stock appreciation rights convertible to 371,824 shares of Pfizer common stock.
Summary
- On March 4, 2025, Douglas M. Lankler, an Executive Vice President at Pfizer Inc., acquired 371,824 stock appreciation rights (SARs).
- These SARs, priced at $25.75 each, are subject to vesting requirements and will be settled in Pfizer common stock on March 4, 2030, the fifth anniversary of the grant date.
- Following this transaction, Lankler directly owns 371,824 derivative securities.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing. It doesn't inherently convey positive or negative sentiment, but rather reports a transaction.
Future Outlook
The stock appreciation rights will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant, subject to vesting requirements.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency into the compensation and equity ownership of Pfizer's executive officers. It reflects a common practice of using stock appreciation rights as part of executive compensation packages in the pharmaceutical industry.
Comparison to Industry Standards
- Stock appreciation rights are a common component of executive compensation packages in large pharmaceutical companies like Pfizer.
- Companies such as Johnson & Johnson, Merck, and AbbVie also utilize similar equity-based compensation methods to align executive interests with shareholder value.
- The vesting schedules and settlement terms of these SARs are likely benchmarked against industry standards to attract and retain top talent.
Stakeholder Impact
- The acquisition of stock appreciation rights by a Pfizer executive aligns their interests with those of shareholders, incentivizing them to increase the company's stock value.
- This transaction has no immediate impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 03/04/2025 | Date of earliest transaction: Douglas M. Lankler acquired stock appreciation rights. |
| 03/04/2030 | Expiration date of the stock appreciation rights; settlement in Pfizer common stock. |
| 03/06/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.